FDA Approves Cimzia Label Update Essential for Childbearing Women with Inflammatory Diseases

FDA Approves Cimzia Label Update Essential for Childbearing Women with Inflammatory Diseases
The U.S. Food and Drug Administration (FDA) recently approved UCB’s request for a label update for Cimzia (certolizumab pegol) indicating low transfer levels of the medication from mother to child through the placenta and breast milk. The move marks an important advance in providing key information on the care of women with Crohn's and other chronic inflammatory diseases throughout their reproductive years. "Recognition and public support for the unique family planning needs of women with chronic inflammatory disease is crucial for this underserved population. The label change for CIMZIA is important for women and their treating physicians to make informed decisions to manage their condition along their
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *